Literature DB >> 18691659

SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging.

Igor Yakushev1, Alexander Hammers, Andreas Fellgiebel, Irene Schmidtmann, Armin Scheurich, Hans-Georg Buchholz, Jürgen Peters, Peter Bartenstein, Klaus Lieb, Mathias Schreckenberger.   

Abstract

Statistical comparisons of [(18)F]FDG PET scans between healthy subjects and patients with Alzheimer's disease (AD) or amnestic mild cognitive impairment (aMCI) using Statistical Parametric Mapping (SPM) usually require normalization of regional tracer uptake via ROIs defined using additional software. Here, we validate a simple SPM-based method for count normalization. FDG PET scans of 21 mild, 15 very mild AD, 11 aMCI patients and 15 age-matched controls were analyzed. First, we obtained relative increases in the whole patient sample compared to controls (i.e. areas relatively preserved in patients) with proportional scaling to the cerebral global mean (CGM). Next, average absolute counts within the cluster with the highest t-value were extracted. Statistical comparisons of controls versus three patients groups were then performed using count normalization to CGM, sensorimotor cortex (SMC) as standard, and to the cluster-derived counts. Compared to controls, relative metabolism in aMCI patients was reduced by 15%, 20%, and 23% after normalization to CGM, SMC, and cluster-derived counts, respectively, and 11%, 21%, and 25% in mild AD patients. Logistic regression analyses based on normalized values extracted from AD-typical regions showed that the metabolic values obtained using CGM, SMC, and cluster normalization correctly classified 81%, 89% and 92% of aMCI and controls; classification accuracies for AD groups (very mild and mild) were 91%, 97%, and 100%. The proposed algorithm of fully SPM-based count normalization allows for a substantial increase of statistical power in detecting very early AD-associated hypometabolism, and very high accuracy in discriminating mild AD and aMCI from healthy aging.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18691659     DOI: 10.1016/j.neuroimage.2008.07.015

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  41 in total

1.  Brain energy metabolism and blood flow differences in healthy aging.

Authors:  Joel Aanerud; Per Borghammer; M Mallar Chakravarty; Kim Vang; Anders B Rodell; Kristjana Y Jónsdottir; Arne Møller; Mahmoud Ashkanian; Manouchehr S Vafaee; Peter Iversen; Peter Johannsen; Albert Gjedde
Journal:  J Cereb Blood Flow Metab       Date:  2012-02-29       Impact factor: 6.200

2.  Empirical derivation of the reference region for computing diagnostic sensitive ¹⁸fluorodeoxyglucose ratios in Alzheimer's disease based on the ADNI sample.

Authors:  Jerod M Rasmussen; Anita Lakatos; Theo G M van Erp; Frithjof Kruggel; David B Keator; James T Fallon; Fabio Macciardi; Steven G Potkin
Journal:  Biochim Biophys Acta       Date:  2011-09-19

3.  Visual and statistical analysis of ¹⁸F-FDG PET in primary progressive aphasia.

Authors:  Jordi A Matías-Guiu; María Nieves Cabrera-Martín; María Jesús Pérez-Castejón; Teresa Moreno-Ramos; Cristina Rodríguez-Rey; Rocío García-Ramos; Aida Ortega-Candil; Marta Fernandez-Matarrubia; Celia Oreja-Guevara; Jorge Matías-Guiu; José Luis Carreras
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-03       Impact factor: 9.236

4.  Metabolic connectivity as index of verbal working memory.

Authors:  Na Zou; Gael Chetelat; Mustafa G Baydogan; Jing Li; Florian U Fischer; Dmitry Titov; Juergen Dukart; Andreas Fellgiebel; Mathias Schreckenberger; Igor Yakushev
Journal:  J Cereb Blood Flow Metab       Date:  2015-03-18       Impact factor: 6.200

5.  The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis.

Authors:  Silvia Morbelli; Javier Arbizu; Jan Booij; Ming-Kai Chen; Gael Chetelat; Donna J Cross; Mehdi Djekidel; Alexander Drzezga; Ozgul Ekmekcioglu; Valentina Garibotto; Swen Hesse; Kazunari Ishii; Lida Jafari; Adriaan A Lammertsma; Ian Law; Dana Mathews; Satoshi Minoshima; Karina Mosci; Marco Pagani; Sabina Pappata; Daniel Hillel Silverman; Alberto Signore; Elsmarieke Van De Giessen; Victor Villemagne; Henryk Barthel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-06       Impact factor: 9.236

6.  A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia.

Authors:  Pasquale Anthony Della Rosa; Chiara Cerami; Francesca Gallivanone; Annapaola Prestia; Anna Caroli; Isabella Castiglioni; Maria Carla Gilardi; Giovanni Frisoni; Karl Friston; John Ashburner; Daniela Perani
Journal:  Neuroinformatics       Date:  2014-10

7.  Glucose metabolism in normal aging and Alzheimer's disease: Methodological and physiological considerations for PET studies.

Authors:  Lisa Mosconi
Journal:  Clin Transl Imaging       Date:  2013-08

Review 8.  Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders.

Authors:  Flavio Nobili; Cristina Festari; Daniele Altomare; Federica Agosta; Stefania Orini; Koen Van Laere; Javier Arbizu; Femke Bouwman; Alexander Drzezga; Peter Nestor; Zuzana Walker; Marina Boccardi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-02       Impact factor: 9.236

9.  Whither the hippocampus? FDG-PET hippocampal hypometabolism in Alzheimer disease revisited.

Authors:  J A Maldjian; C T Whitlow
Journal:  AJNR Am J Neuroradiol       Date:  2012-06-14       Impact factor: 3.825

10.  Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters.

Authors:  Artur Martins Coutinho; Geraldo F Busatto; Fábio Henrique de Gobbi Porto; Daniele de Paula Faria; Carla Rachel Ono; Alexandre Teles Garcez; Paula Squarzoni; Fábio Luiz de Souza Duran; Maira Okada de Oliveira; Eduardo Sturzeneker Tres; Sonia Maria Dozzi Brucki; Orestes Vicente Forlenza; Ricardo Nitrini; Carlos Alberto Buchpiguel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-02-13       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.